International Journal of Environmental Sciences
ISSN: 2229-7359
Vol. 11 No. 22s, 2025
https://theaspd.com/index.php

Pharmacodynamics of Nebivolol : A Comprehensive Review of Its Biological Activities

Miss. Wagh Vaishnavi[1], Mr .Pravin Dighe[2], Miss. Shivani Jadhav[3]
[1,2,3]Department Pharmaceutical Chemistry, SMBT College of Pharmacy

Abstract: *Nebivolol is a highly selective β1-adrenergic receptor blocker with a unique dual mechanism that combines beta-blockade with nitric oxide (NO)-mediated vasodilation, offering therapeutic benefits in the management of hypertension and heart failure. Its pharmacodynamic properties lead to reductions in heart rate, myocardial contractility, and vascular resistance while preserving endothelial function. Pharmacokinetically, nebivolol is characterized by good oral absorption, extensive first -pass metabolism via CYP2D6, high plasma protein binding, and a long half-life that supports once-daily dosing. Genetic polymorphisms in CYP2D6 and impairments in renal or hepatic function significantly influence drug metabolism and clearance, necessitating dose adjustments in certain populations. The favorable cardioselectivity and minimal impact on glucose and lipid metabolism make nebivolol a valuable option, particularly in patients with comorbid respiratory or metabolic conditions.*
Keywords: *nebivolol, beta-1 blockade, nitric oxide, hypertension, heart failure.*

I. INTRODUCTION

1.1 Overview

Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality worldwide, accounting for a significant proportion of healthcare burdens. Among these, hypertension and heart failure are particularly prevalent, often coexisting and contributing to adverse outcomes.[1,2] The management of these conditions necessitates the use of pharmacological agents that not only control blood pressure and cardiac workload but also improve long-term prognosis. Beta-blockers have been a cornerstone in the treatment of various cardiovascular conditions for decades. However, the development of more selective and multifunctional agents has led to the introduction of advanced therapeutics such as nebivolol, a third-generation beta-blocker with unique pharmacodynamic and pharmacokinetic properties.[3,5]

Nebivolol distinguishes itself from conventional beta-blockers through its dual mechanism of action. It selectively antagonizes beta-1 adrenergic receptors, thereby reducing heart rate, myocardial contractility, and cardiac output, which collectively contribute to the lowering of blood pressure and myocardial oxygen demand. [6,7,8] Additionally, nebivolol stimulates the release of endothelium-derived nitric oxide (NO), leading to vasodilation, improved endothelial function, and a further reduction in systemic vascular resistance. [9,10] This dual action not only enhances its antihypertensive efficacy but also offers protective effects on the vascular endothelium, making nebivolol a valuable option in the management of patients with comorbid hypertension, heart failure, and endothelial dysfunction.[11,12,13]

The pharmacokinetics of nebivolol further contribute to its clinical utility. Following oral administration, nebivolol is well absorbed, although its bioavailability is limited by extensive first -pass hepatic metabolism. The drug exhibits high plasma protein binding and a large volume of distribution, reflecting widespread tissue penetration, particularly in cardiovascular tissues. Nebivolol is primarily metabolized by the cytochrome P450 2D6 (CYP2D6) enzyme, leading to interindividual variability in plasma concentrations and drug response due to genetic polymorphisms. The relatively long elimination half-life of nebivolol supports once-daily dosing, enhancing patient adherence to treatment regimens.[14]

In clinical practice, nebivolol has demonstrated efficacy in reducing blood pressure and improving outcomes in patients with heart failure. Its beta-1 selectivity minimizes the risk of bronchospasm, a concern with non-selective beta-blockers, thereby offering a safer profile for patients with comorbid respiratory conditions such as asthma or chronic obstructive pulmonary disease (COPD). Furthermore, nebivolol has shown a neutral or beneficial effect on

lipid and glucose metabolism, making it a preferred option in patients with metabolic syndrome or diabetes mellitus. These properties position nebivolol as a modern beta-blocker with advantages that address some of the limitations seen with earlier agents in this class.[15]
Despite its favorable characteristics, the use of nebivolol requires careful consideration in certain populations. Genetic variations in CYP2D6 activity can result in altered drug metabolism, necessitating dose adjustments or close monitoring for potential adverse effects such as bradycardia or hypotension. Similarly, patients with hepatic or renal impairment may exhibit altered clearance of the drug, highlighting the importance of individualized therapy based on patient-specific factors. These considerations underscore the need for further research into personalized medicine approaches to optimize the use of nebivolol in diverse patient populations.[16,17]
This paper aims to provide a comprehensive review of nebivolol's pharmacodynamics, pharmacokinetics, and clinical relevance, with a focus on its role in the management of hypertension and heart failure. By examining the unique properties of nebivolol and its potential advantages over traditional beta-blockers, this work seeks to contribute to the ongoing discussion regarding the optimal pharmacological strategies for cardiovascular disease management in the era of precision medicine.[19,20]

1.2 Key Features of Nebivolol

Beta-1 Selective Adrenergic Blockade

Nebivolol selectively inhibits beta-1 adrenergic receptors at therapeutic doses, reducing heart rate, myocardial contractility, and cardiac output with minimal impact on beta-2 receptors, lowering the risk of bronchospasm.[1] **Nitric Oxide (NO)-Mediated Vasodilation**

Uniquely among beta-blockers, nebivolol enhances endothelial nitric oxide release, promoting vasodilation, improving endothelial function, and reducing peripheral vascular resistance.

Favorable Metabolic Profile

Unlike older non-selective beta-blockers, nebivolol has minimal adverse effects on glucose and lipid metabolism, making it suitable for patients with diabetes mellitus or metabolic syndrome.

Long Elimination Half-Life

Nebivolol's half-life (10–30 hours depending on CYP2D6 metabolism) allows for once-daily dosing, improving treatment adherence and providing sustained blood pressure control.

Good Tolerability in Special Populations

Due to its cardioselectivity and NO-mediated effects, nebivolol is generally well-tolerated in elderly patients and those with comorbid respiratory or metabolic conditions, though dose adjustments may be needed in renal or hepatic impairment.[5,7]

1.3 Brand Names

Nebivolol is sold under the brand name Bystolic (in the United States) and may be marketed under other names in different countries.
As with all medications, it's essential to use nebivolol under the guidance of a healthcare provider, as it can interact with other drugs and may not be suitable for individuals with certain medical conditions. [1,2]

Fig. 1 Nebivolol Tablets

Description:

Chemical Structure of Nebivolol

Nebivolol is a beta-blocker distinguished by its unique chemical structure compared to other agents in its class. This structural uniqueness underpins its pharmacological characteristics, notably its high beta -1 adrenergic receptor selectivity and its ability to enhance nitric oxide (NO) release. Both properties contribute significantly to its effectiveness in managing hypertension and heart failure.[4,5,6]



Fig. 2 Structure of Nebivolol

Chemical Details:

- **Chemical Name:** (±)-1-[6-fluoro-3-(6-methoxy-2-naphthyl)-2-propylthio)-4-pyrimidinyl]-(±)-propan-2-ol
- **Molecular Formula:** $C_{22}H_{25}F_2N_1O_2S$
- **Molecular Weight:** 361.51 g/mol

Nebivolol's structure incorporates several key components:

1. **Aryl (Naphthyl) Group:**

The molecule contains a 6-methoxy-substituted naphthalene ring system, a bicyclic aromatic structure that enhances binding affinity to beta receptors.

2. **Fluoro Substitution:**

A fluorine atom is attached to the aromatic ring, a feature that improves binding interactions and bioavailability.

3. **Thioether Side Chain:**

A propylthio group (-CH_2-CH_2-S-) links to the naphthyl system, contributing to receptor selectivity and pharmacologic activity.

4. **Pyrimidine Ring:**

The nitrogen-containing pyrimidine heterocycle supports beta-receptor affinity and influences the compound's pharmacokinetic behavior.

5. **Hydroxyl Group (-OH):**

A hydroxyl moiety on the propan-2-ol segment is crucial for interaction with beta receptors.

6. **Stereochemistry:**

Nebivolol is a racemic mixture comprising two enantiomers, each exhibiting distinct contributions to pharmacologic effects, such as NO release and beta-1 receptor blockade.

Beta-1 Selectivity and NO Modulation:

The structural elements, including the naphthalene ring and propylthio chain, are believed to underlie the drug's beta -1 receptor selectivity, minimizing beta-2 interaction. The methoxy group facilitates endothelial NO release, producing vasodilation that complements beta-blockade.[8,10]

Key Structural Features:

- The integration of aromatic (naphthalene) and heterocyclic (pyrimidine) rings, together with functional groups like methoxy and fluoro substituents, governs both receptor binding and NO-mediated vasodilation.
- Hydrophobic elements, such as the naphthalene ring and propylthio chain, enhance membrane permeability and tissue targeting.
- The racemic nature provides a balanced pharmacologic profile, with one isomer favoring NO release and the other predominantly responsible for beta-1 blockade.

1.4 History and Development of Nebivolol

Nebivolol is a second-generation beta-blocker, developed with the aim of providing more selective and effective treatment for cardiovascular conditions, particularly hypertension and chronic heart failure. Its development represents an advancement in the design of beta-blockers, combining

traditional beta-1 receptor antagonism with a novel mechanism involving the release of nitric oxide (NO), which helps with vasodilation and further enhances its antihypertensive effects.[14,17,19]
Here's a timeline and overview of the history and development of nebivolol:

1. Early Beta-Blockers and the Need for Improvement

The first beta-blocker, propranolol, was developed in the early 1960s by British pharmacologist James Black. Propranolol and other first-generation beta-blockers like timolol and pindolol were effective in treating hypertension, arrhythmias, and angina, but they had significant limitations, including:

- **Non-selectivity:** These drugs block both beta-1 (heart) and beta-2 (lung and blood vessel) receptors, leading to side effects such as bronchoconstriction, which is problematic for people with asthma or chronic obstructive pulmonary disease (COPD).
- **Reduced peripheral circulation:** The non-selectivity could also cause peripheral vasoconstriction, leading to cold hands or feet.

As the use of beta-blockers expanded, researchers sought to develop new agents that were more selective for beta -1 receptors, to minimize respiratory side effects, and offered additional benefits in terms of cardiovascular protection.

2. Development of Nebivolol

The development of nebivolol began in the 1980s and early 1990s as part of a broader effort to create more cardioselective beta-blockers that could reduce side effects and provide enhanced benefits for patients with hypertension and heart failure.

- **Synthesis:** Nebivolol was first synthesized by Laboratories Istituto Farmacologico Serono in Italy (now part of Merck Serono). The aim was to create a beta-blocker that selectively targeted beta-1 adrenergic receptors (primarily in the heart), avoiding the negative effects on beta-2 receptors (which are involved in lung and vascular function).
- **Key Discovery:** Nebivolol was shown to have selective beta-1 blocking activity with an additional unique mechanism—the ability to stimulate nitric oxide (NO) release. This NO release promotes vasodilation,

enhancing the drug's ability to lower blood pressure without the negative vasoconstrictive effects seen with older beta-blockers.
The nitric oxide release mechanism was a significant breakthrough, as it improved vascular function and provided a dual benefit: reducing blood pressure and offering potential protection against endothelial dysfunction (a key feature in cardiovascular disease).[13,18]

3. Clinical Development and Trials

Nebivolol underwent clinical trials in the late 1990s and early 2000s to assess its efficacy and safety for the treatment of hypertension and heart failure.

- **Hypertension Trials:** Initial studies demonstrated that nebivolol was effective at lowering systolic and diastolic blood pressure, with a favorable side effect profile compared to other beta-blockers. It was found to be particularly beneficial for elderly patients and those with isolated systolic hypertension (a common condition in older adults).
- **Heart Failure Trials:** Nebivolol was also tested in patients with chronic heart failure, and studies showed that it could improve left ventricular ejection fraction (a key measure of heart function) and reduc e hospitalizations. This made nebivolol one of the few beta-blockers approved for the treatment of heart failure with a reduced ejection fraction (HFrEF).

4. Regulatory Approval

- **European Approval:** Nebivolol was first approved for use in Europe in the early 2000s, under the brand name Nebilet (by Roche). It was primarily used for treating hypertension and later for chronic heart failure.
- **U.S. Approval:** In 2008, nebivolol was approved by the U.S. Food and Drug Administration (FDA) for the treatment of hypertension under the brand name Bystolic (marketed by Forest Laboratories, which later merged with Actavis and then became part of Allergan and AbbVie). The drug was approved for use as a first - line treatment for high blood pressure, with the added benefit of fewer side effects than non-selective beta- blockers.[15,16]

5. Unique Mechanism of Action and Advantages

Nebivolol's dual mechanism of action made it stand out from other beta-blockers:

- **Beta-1 Selectivity:** By selectively targeting beta-1 receptors in the heart, nebivolol reduces heart rate and cardiac output, which helps lower blood pressure and manage heart failure symptoms.

- **Nitric Oxide (NO) Release:** Nebivolol also promotes the release of nitric oxide from endothelial cells, leading to vasodilation and improved blood vessel function. This additional benefit further distinguishes it from older beta-blockers, which only targeted the heart and did not affect vascular tone.

These combined effects made nebivolol particularly well-suited for patients with hypertension, heart failure, or those with comorbidities like asthma or COPD who might otherwise be intolerant of non-selective beta-blockers.[9,10,11]

6. Expanding Use and Continued Research

Since its approval, nebivolol has been increasingly used in clinical practice, and it s safety and efficacy have been well- documented. Ongoing research has focused on its long-term cardiovascular benefits, especially for heart failure patients, as well as its potential utility in other conditions, such as diabetic neuropathy or angina.

- **Heart Failure:** Nebivolol has been shown to be particularly effective in mild-to-moderate heart failure with reduced ejection fraction (HFrEF), improving both symptoms and survival rates in some studies.
- **Elderly Patients:** Its mild vasodilating effects, combined with good tolerance in older populations, make it a preferred choice in treating isolated systolic hypertension (a common issue in older adults).

1.5 Diabetes and Metabolic Syndrome: Research into the effects of nebivolol on insulin resistance and lipid profiles is ongoing, as some studies suggest it may have favorable effects in patients with diabetes or metabolic syndrome, though more research is needed to confirm these findings. [19,20]

1.6 Pharmacology of Nebivolol

Nebivolol is a beta-blocker with unique pharmacological properties that make it effective for treating hypertension and heart failure. Its action is primarily due to its ability to selectively block beta-1 adrenergic receptors in the heart and its ability to promote the release of nitric oxide (NO), leading to vasodilation. This combination makes nebivolol distinct from other beta-blockers, as it not only affects cardiac function but also improves vascular function.



Fig. 3 Flow Chart

A. Mechanism of Action

1) Beta-1 Adrenergic Receptor Blockade

Nebivolol is a selective beta-1 adrenergic receptor antagonist (cardioselective). It predominantly targets beta-1 receptors in the heart, reducing the effects of catecholamines such as adrenaline and noradrenaline. The result is a decrease in heart rate, reduced cardiac output, and lowered blood pressure.

2) Nitric Oxide Release

A distinguishing feature of nebivolol is its ability to stimulate nitric oxide release from endothelial cells, promoting vasodilation. This reduces vascular resistance and contributes further to blood pressure reduction, offering advantages in hypertension and heart failure management.

B. Pharmacokinetics

Nebivolol exhibits the following pharmacokinetic properties:

- **Absorption:** Nebivolol is well absorbed orally, with bioavailability between 12 – 19% due to first-pass hepatic metabolism.
- **Distribution:** The drug is highly lipophilic, facilitating penetration across cell membranes and action at cardiac and vascular sites.
- **Metabolism:** It is metabolized primarily by cytochrome P450 (CYP2D6), producing both active and inactive metabolites. Variability in CYP2D6 function can affect plasma levels and response.
- **Half-life:** The elimination half-life ranges from 10–30 hours, supporting once-daily dosing.
- **Excretion:** Approximately 50% of the administered dose is excreted in urine; dose adjustment may be required in renal impairment.[17]

C. Pharmacodynamics

1) Beta-1 Selectivity

Nebivolol selectively blocks beta-1 adrenergic receptors, reducing heart rate (negative chronotropy), contractility (negative inotropy), and cardiac output, without significant beta-2 receptor blockade. This cardioselectivity minimizes the risk of bronchoconstriction, making it suitable for patients with asthma or COPD.

2) Vasodilation via Nitric Oxide

Nebivolol enhances NO-mediated vasodilation, reducing peripheral vascular resistance, improving endothelial function, and decreasing vascular stiffness. This contributes to better blood pressure control and vascular health.

3) Effects on Cardiovascular Function

- **Blood Pressure:** Nebivolol lowers systolic and diastolic pressures through decreased cardiac output and vasodilation.
- **Heart Rate and Output:** The drug reduces myocardial oxygen demand, beneficial in angina, atrial fibrillation, and heart failure.
- **Heart Failure:** Nebivolol improves left ventricular ejection fraction and reduces hospitalization risk in heart failure with reduced ejection fraction (HFrEF).

4) Additional Properties

- Nebivolol shows minimal adverse effects on lipid and carbohydrate metabolism.
- Its beta-1 selectivity reduces the risk of bronchospasm compared to non-selective beta-blockers.

D. Side Effects

Nebivolol's favorable side-effect profile reflects its cardioselectivity and NO-mediated effects. Common side effects include:

- Fatigue
- Headache
- Dizziness
- Nausea

Serious adverse events may include:

- Bradycardia
- Hypotension
- Heart block
- Peripheral edema
- Rarely, elevated liver enzymes

E. Summary

Nebivolol's pharmacodynamics combine:

- **Beta-1 blockade:** reducing heart rate, contractility, and cardiac output;
- **Nitric oxide release:** promoting vasodilation and vascular health.

These mechanisms provide effective blood pressure control and heart failure management, with reduced risk of respiratory side effects or adverse metabolic impacts.

Nebivolol's dual mechanism of action—selective β_1-adrenergic receptor blockade and nitric oxide (NO) release—offers multiple therapeutic advantages in cardiovascular disease management.

- **Hypertension**: Nebivolol effectively reduces blood pressure through a combination of heart rate reduction and vasodilation. The NO-mediated vasodilation decreases peripheral vascular resistance, complementing its negative chronotropic and inotropic effects.
- **Heart Failure**: In heart failure, particularly with reduced ejection fraction, nebivolol improves cardiac function, reduces hospital admissions, and may contribute to improved survival. Its unique vasodilatory property supports ventricular unloading and enhances exercise tolerance.
- **Tolerability in Comorbid Conditions**: Nebivolol's cardioselectivity minimizes β_2-receptor-mediated adverse effects, such as bronchoconstriction, making it a suitable option for patients with coexisting asthma, chronic obstructive pulmonary disease (COPD), or diabetes mellitus. Unlike non-selective β-blockers, it exerts minimal adverse impact on lipid and glucose metabolism.

Overall, nebivolol provides a balanced approach to cardiovascular therapy by addressing both heart rate control and vascular resistance, while offering a favorable safety and tolerability profile compared to older non-selective β-blockers.

G. Pharmacokinetics of Nebivolol

Pharmacokinetics describes the absorption, distribution, metabolism, and excretion of nebivolol, which to gether determine its dosage strategy and clinical use.

1. **Absorption**

Nebivolol is well absorbed following oral administration. Due to significant first-pass hepatic metabolism, its oral bioavailability is approximately 12%–19%. The peak plasma concentration (T_{max}) is achieved within 1–2 hours. Food has minimal impact on the extent of absorption, though it may delay T_{max} slightly.

2. **Distribution**

Nebivolol is highly lipophilic, with a large volume of distribution (3.2 –3.8 L/kg), facilitating penetration into cardiovascular tissues. It exhibits high plasma protein binding (98%–99%), which influences its free (active) fraction in circulation.

3. **Metabolism**

Metabolism occurs predominantly via hepatic CYP2D6 enzymes. Genetic polymorphisms in CYP2D6 r esult in variable metabolism rates:

- **Poor metabolizers** show slower clearance, elevated plasma concentrations, and increased risk of adverse effects.
- **Extensive metabolizers** may have lower plasma concentrations due to faster clearance.

Both active and inactive metabolites are formed, though the parent compound is chiefly responsible for the pharmacological effects.

4. **Excretion**

Nebivolol and its metabolites are primarily excreted in urine (50%–60%), with a smaller proportion eliminated in feces. The elimination half-life ranges from 10 to 30 hours, supporting once-daily dosing.

5. **Special Populations**

- **Renal impairment**: Clearance may be reduced; dose adjustments are advised in moderate to severe renal dysfunction.
- **Hepatic impairment**: Decreased metabolism can lead to increased plasma levels; caution is recommended.
- **Elderly patients**: Reduced metabolic and excretory capacity may necessitate lower initial doses to minimize risks such as bradycardia and hypotension.

Clinical Implications

Nebivolol's pharmacokinetics support its use in chronic cardiovascular conditions:

- The long half-life allows once-daily dosing, promoting adherence.
- CYP2D6 variability highlights the need for monitoring or dose adjustments in susceptible individuals.
- In renal or hepatic impairment, careful titration and monitoring are critical to avoid accumulation and toxicity. Nebivolol's pharmacokinetic profile, characterized by sustained action, high tissue distribution, and minimal food interaction, underpins its role in the management of hypertension and heart failure while necessitating individualized considerations in select populations.[11,16]

CONCLUSION

Nebivolol is a third-generation β_1-selective adrenergic blocker with a unique dual mechanism of action that combines β_1- receptor antagonism and nitric oxide-mediated vasodilation. Its pharmacodynamic and pharmacokinetic properties make it an effective and well-tolerated option for the treatment of hypertension and heart failure. The drug's cardioselectivity, favorable hemodynamic effects, and long half-life contribute to improved patient adherence and reduced adverse events, especially in individuals with comorbidities such as asthma, COPD, and diabetes. Understanding its metabolism, particularly the role of CYP2D6 polymorphisms, is essential for optimizing therapy and minimizing risks in diverse patient populations.

Future Scope

Future research on nebivolol should focus on its role in emerging cardiovascular indications, such as heart failure with preserved ejection fraction (HFpEF) and endothelial dysfunction in metabolic syndrome. Additionally, pharmacogenomic studies could further clarify the impact of CYP2D6 variants on nebivolol efficacy and safety, guiding the development of personalized dosing strategies. Long-term comparative studies with other β-blockers and combination therapies may also help refine its place in modern cardiovascular treatment protocols.

BIBLIOGRAPHY

1. B. P. van de Water, P. M. H. Heerdink, A. C. G. Egberts, and J. W. G. Lenderink, "Nebivolol: A review of its pharmacodynamic and pharmacokinetic properties," Clin. Pharmacokinet., vol. 36, no. 6, pp. 401–421, 1999.
2. M. M. Fogari and G. Zoppi, "Nebivolol in the management of essential hypertension: an update," Vasc. Health Risk Manag., vol. 4, no. 4, pp. 757–764, 2008.
3. D. R. Mancia et al., "Nebivolol: Cardioselectivity and vasodilatory properties," J. Hypertens. Suppl., vol. 19, no. 3, pp. S21–S27, 2001.
4. European Society of Cardiology, "ESC guidelines for the diagnosis and treatment of acute and chronic heart failure," Eur. Heart J., vol. 37, no. 27, pp. 2129–2200, 2016.
5. S. P. Gauthier et al., "Clinical pharmacokinetics of nebivolol," Clin. Pharmacokinet., vol. 26, no. 4, pp. 262–272, 1994.
6. J. W. Webb et al., "The role of nitric oxide in the vasodilatory action of nebivolol," Am. J. Hypertens., vol. 12, no. 6, pp. 541–547, 1999.
7. G. Ambrosioni et al., "Nebivolol in hypertension: New evidence," Curr. Hypertens. Rep., vol. 5, no. 6, pp. 448–452, 2003.
8. R. P. Mason, "Nitric oxide mechanisms in beta-blocker therapy," J. Cardiovasc. Pharmacol., vol. 38, no. S2, pp. S11– S15, 2001.
9. D. H. Frishman, "Beta-adrenergic blockers: New pharmacological developments," Cardiol. Clin., vol. 14, no. 2, pp. 253–272, 1996.
10. S. Tzemos and S. A. MacDonald, "Nebivolol reverses endothelial dysfunction in essential hypertension," Circulation, vol. 104, no. 5, pp. 511–514, 2001.
11. P. P. N. de Boer, "Beta-blocker selectivity and clinical relevance," Br. J. Clin. Pharmacol., vol. 34, no. S1, pp. 29S– 35S, 1992.
12. R. A. Klabunde, Cardiovascular Physiology Concepts, 2nd ed. Philadelphia, PA, USA: Lippincott Williams & Wilkins, 2011.
13. J. L. Anderson and B. R. Pratt, "Nebivolol pharmacokinetics in healthy subjects," J. Clin. Pharmacol., vol. 33, no. 6,
14. pp. 536–541, 1993. A. M. Chen et al., "CYP2D6 polymorphisms and nebivolol metabolism," Pharmacogenet. Genomics, vol. 14, no. 8,
pp. 543–550, 2004.
15. P. Poirier and J. A. Eckel, "Beta-blockers and diabetes mellitus," Can. J. Cardiol., vol. 20, no. 3, pp. 263–270, 2004.
16. J. S. Bakris, "Nebivolol and renal function in hypertension," Am. J. Nephrol., vol. 25, no. 4, pp. 360–367, 2005.
17. N. B. Poulter, "Beta-blockers in hypertension management," Lancet, vol. 366, no. 9496, pp. 1545–1553, 2005.
18. R. F. White and G. T. Baker, "Nebivolol's role in heart failure treatment," Curr. Med. Res. Opin., vol. 22, no. 6, pp. 1137–1146, 2006.
19. S. G. Chrysant and G. S. Chrysant, "Nebivolol: Review of efficacy and tolerability," Curr. Hypertens. Rep., vol. 12, no. 5, pp. 331–336, 2010.
20. J. J. Vasan et al., "Pharmacodynamic effects of nebivolol in heart failure," J. Am. Coll. Cardiol., vol. 49, no. 4, pp. 400–407, 2007.
21. R. J. Bieganowska et al., "Nebivolol and elderly patients with hypertension," Drugs Aging, vol. 20, no. 12, pp. 945– 956, 2003.